Literature DB >> 33539569

Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity.

Kevin J Downes1,2,3,4, Jennifer L Goldman5,6.   

Abstract

Antimicrobials are a common cause of drug toxicity. Understanding the relationship between systemic antimicrobial exposure and toxicity is necessary to enable providers to take a proactive approach to prevent undesired drug effects. When an exposure threshold has been defined that predicts drug toxicity, therapeutic drug monitoring (TDM) can be performed to assure drug exposure does not exceed the defined threshold. Although some antimicrobials have well-defined dose-dependent toxicities, many other exposure-toxicity relationships have either not been well-defined or, in some cases, not been evaluated at all. In this review, we examine the relationship between exposures and toxicities for antibiotic, antifungal, and antiviral agents. Furthermore, we classify these relationships into four categories: known association between drug exposure and toxicity such that clinical implementation of a specific exposure threshold associated with toxicity for TDM is supported (category 1), known association between drug exposure and toxicity but the specific exposure threshold associated with toxicity is undefined (category 2), association between drug exposure and toxicity has been suggested but relationship is poorly defined (category 3), and no known association between drug exposure and toxicity (category 4). Further work to define exposure-toxicity thresholds and integrate effective TDM strategies has the potential to minimize many of the observed antimicrobial toxicities.
© 2021 The Authors. Clinical Pharmacology & Therapeutics © 2021 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33539569      PMCID: PMC8634201          DOI: 10.1002/cpt.2190

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  120 in total

1.  Current use of daptomycin and systematic therapeutic drug monitoring: Clinical experience in a tertiary care institution.

Authors:  Alicia Galar; Patricia Muñoz; Maricela Valerio; Emilia Cercenado; Xandra García-González; Almudena Burillo; Mar Sánchez-Somolinos; Miriam Juárez; Eduardo Verde; Emilio Bouza
Journal:  Int J Antimicrob Agents       Date:  2018-09-19       Impact factor: 5.283

Review 2.  Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.

Authors:  Michael J Dolton; John E Ray; Deborah Marriott; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

3.  Evaluation of Daptomycin-Induced Cellular Membrane Injury in Skeletal Muscle.

Authors:  Takehiro Yamada; Shuhei Ishikawa; Nobuhisa Ishiguro; Masaki Kobayashi; Ken Iseki
Journal:  Biol Pharm Bull       Date:  2020-06-23       Impact factor: 2.233

4.  Relationship of Ganciclovir Therapeutic Drug Monitoring with Clinical Efficacy and Patient Safety.

Authors:  Brianne M Ritchie; Jason N Barreto; Erin F Barreto; Stacy A Crow; Ross A Dierkhising; Paul J Jannetto; Pritish K Tosh; Raymund R Razonable
Journal:  Antimicrob Agents Chemother       Date:  2019-02-26       Impact factor: 5.191

5.  Nephrotoxicity associated with amphotericin B deoxycholate in neonates.

Authors:  Jennifer Le; Felice C Adler-Shohet; Christine Nguyen; Jay M Lieberman
Journal:  Pediatr Infect Dis J       Date:  2009-12       Impact factor: 2.129

6.  Drug monitoring during the treatment of AIDS-associated Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole.

Authors:  H Klinker; P Langmann; M Zilly; E Richter
Journal:  J Clin Pharm Ther       Date:  1998-04       Impact factor: 2.512

7.  Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.

Authors:  Sekai Chideya; Carla A Winston; Charles A Peloquin; William Z Bradford; Philip C Hopewell; Charles D Wells; Arthur L Reingold; Thomas A Kenyon; Themba L Moeti; Jordan W Tappero
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

8.  Bone marrow toxicity associated with 5-fluorocytosine therapy.

Authors:  C A Kauffman; P T Frame
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

Review 9.  An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency.

Authors:  Andrew C Bennett; Charles L Bennett; Bartlett J Witherspoon; Kevin B Knopf
Journal:  Expert Opin Drug Saf       Date:  2019-09-18       Impact factor: 4.250

10.  Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Yukihiro Hamada; Issei Tokimatsu; Hiroshige Mikamo; Masao Kimura; Masafumi Seki; Shunji Takakura; Norio Ohmagari; Yoshiko Takahashi; Kei Kasahara; Kazuaki Matsumoto; Kenji Okada; Masahiro Igarashi; Masahiro Kobayashi; Takahiro Mochizuki; Yoshifumi Nishi; Yusuke Tanigawara; Toshimi Kimura; Yoshio Takesue
Journal:  J Infect Chemother       Date:  2013-05-15       Impact factor: 2.211

View more
  1 in total

Review 1.  Successful Integration of Clinical Pharmacists in an OPAT Program: A Real-Life Multidisciplinary Circuit.

Authors:  Sara Ortonobes; Abel Mujal-Martínez; María de Castro Julve; Alba González-Sánchez; Rafael Jiménez-Pérez; Manuel Hernández-Ávila; Natalia De Alfonso; Ingrid Maye-Pérez; Teresa Valle-Delmás; Alba Rodríguez-Sánchez; Jessica Pino-García; Mònica Gómez-Valent
Journal:  Antibiotics (Basel)       Date:  2022-08-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.